Skip to main content
Premium Trial:

Request an Annual Quote

Agilent to Work With Icoria on $11.7M NIST Project

NEW YORK, Oct. 7 (GenomeWeb News) - The National Institute of Standards and Technology Advanced Technology Program approved Agilent Technologies to collaborate with Icoria on a drug-reaction bioinformatics project funded by a $11.7 million ATP grant, said Icoria in a statement today.


The ATP awarded the grant in support of its Target Assessment Technologies Suite, said the statement. The TATS project works to develop software and database technologies useful in identifying gene function and associated "leads for new pharmaceutical and chemical products rapidly, reliably, and efficiently," according to the ATP website.


Agilent takes the place of LION Bioscience, which withdrew from the project, said the statement.


Agilent will use its Agilent Synapsia Informatics Workbench, a data association framework for use in the study of "vast amounts" of genomic, proteomic, toxicologic, and drug efficacy data, the company said. The grant will fund an "enhancement" of the framework, and the two companies will work toward developing a commercializable software product, the company added.


"We look forward to working with Agilent in the ongoing development of important new technologies that enable scientists to gain greater insight into the development of safer and more effective medications," said Thomas J. Colatsky, Icoria vice president of Human Health Research, said in the statement.


Icoria has completed the first of three grant milestones, "the development, validation, and analysis of a coherent data set" concerning rat liver injury induced by acetaminophen, and the discovery of hepatoxicity biomarkers, said the company.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.